The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance

• Published in: Oncotarget Vol. 7; no. 50; pp. 82783 - 82797
• Main Authors: Al Fayi, Majed Saad, Gou, Xiaojun, Forootan, Shiva S, Al-Jameel, Waseem, Bao, Zhengzheng, Rudland, Philip R, Cornford, Philip A, Hussain, Syed A, Ke, Youqiang
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 13-12-2016
• Subjects: Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cell Line, Tumor; Cell Movement; Fatty Acid-Binding Proteins - genetics; Fatty Acid-Binding Proteins - metabolism; Gastrointestinal Hormones - genetics; Gastrointestinal Hormones - metabolism; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Neoplasm Grading; Neoplasm Invasiveness; Predictive Value of Tests; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Prostatic Neoplasms - therapy; Receptors, Androgen - metabolism; Research Paper; RNA Interference; RNA, Messenger - genetics; Time Factors; Up-Regulation; FABP9; gleason scores; prostate cancer; prognosis; PSA
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.12635

In contrast to numerous studies conducted to investigate the crucial role of fatty acid binding protein 5 (FABP5) in prostate cancer, investigations on the possible involvement of other FABPs are rare. Here we first measured the mRNA levels of 10 FABPs in benign and malignant prostate cell lines and identified the differentially expressed FABP6 and FABP9 mRNAs whose levels in all malignant cell lines were higher than those in the benign cells. Thereafter we assessed the expression status of FABP6 and FABP9 in both prostate cell lines and in human tissues. FABP6 protein was overexpressed only in 1 of the 5 malignant cell lines and its immunostaining intensities were not significantly different between benign and malignant prostate tissues. In contrast, FABP9 protein was highly expressed in highly malignant cell lines PC-3 and PC3-M, but its level in the benign PNT-2 and other malignant cell lines was not detectable. When analysed in an archival set of human prostate tissues, immunohistochemical staining intensity for FABP9 was significantly higher in carcinomas than in benign cases and the increase in FABP9 was significantly correlated with reduced patient survival times. Moreover, the increased level of staining for FABP9 was significantly associated with the increased joint Gleason scores (GS) and androgen receptor index (AR). Suppression of FABP9 expression in highly malignant PC3-M cells inhibited their invasive potential. Our results suggest that FABP9 is a valuable prognostic marker to predict the outcomes of prostate cancer patients, perhaps by playing an important role in prostate cancer cell invasion.